Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00170742|
Recruitment Status : Terminated (trial stopped on Sept 24, 2007)
First Posted : September 15, 2005
Last Update Posted : August 12, 2008
|Condition or disease||Intervention/treatment||Phase|
|Proliferative Diabetic Retinopathy||Drug: Octreotide, 30 mg i.m. LAR formulation||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||17 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open Label, Controlled Study on the Efficacy and Safety of Octreotide i.m. in Patients With Proliferative Diabetic Retinopathy (PDR) After Start of Laser Coagulation|
|Study Start Date :||December 2003|
|Actual Primary Completion Date :||May 2006|
- regression of neovascularization.
- Determine tolerability and safety
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00170742
|Study Chair:||Novartis Customer Information||Novartis AG|